Raleigh, United States
Kinvard Bio is an emerging player in the biotech sector, founded in 2024, with a focus on creating antibiotics that target ribosomes to address drug-resistant bacterial infections. This innovative approach is supported by their proprietary chemistry platform technology, the fruit of exclusive research from the Myers lab at Harvard University and funded by the Kineticos AMR Accelerator Fund I (KAMRA I).
The company's flagship technology, oxepanoprolinamides (OPPs), is a novel class of lincosamide antibiotics designed for effective ribosomal binding. Initial preclinical studies suggest these compounds are highly effective against both Gram-positive and Gram-negative bacterial pathogens, positioning Kinvard Bio to meet significant unmet clinical needs while presenting substantial commercial potential.
While details on investments and headquarters location remain undisclosed, Kinvard Bio leverages its strong academic and funding partnerships to tackle the critical issue of antimicrobial resistance.
